Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias
- PMID: 16389311
- PMCID: PMC1144491
- DOI: 10.1602/neurorx.2.3.480
Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias
Abstract
Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.
References
-
- Sudarsky L, Coutinho P. Machado-Joseph disease. Clin Neurosci 3: 17–22, 1995. - PubMed
-
- Zoghbi HY, Orr H T. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23: 217–247, 2000. - PubMed
-
- Nakamura K, Jeong S Y, Uchihara T, Anno M, Nagashima K, Nagashima T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 10: 1441–1448, 2001. - PubMed
-
- Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 8: 221–228, 1994. - PubMed
-
- Takiyama Y, Sakoe K, Nakano I, Nishizawa M. Machado-Joseph disease: cerebellar ataxia and autonomic dysfunction in a patient with the shortest known expanded allele (56 CAG repeat units) of the MJD1 gene. Neurology 49: 604–606, 1997. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
